India’s new CDSCO guidelines for expert panels in drug and device approvals and their impact on innovation
India’s CDSCO guidelines aim to streamline drug approvals, boosting innovation.
Category: Pharmaceuticals & Healthcare Products
Pharmaceuticals & Healthcare Products
The pharma export portal shift and its implications for Indian exporters
India’s pharma export portal shift reshapes global trade strategies.
Growth drivers behind India’s pharma market growing 8.4% in FY25, especially in chronic therapies
India’s pharma market thrives, driven by chronic therapy demand.
Lessons from the price erosion of empagliflozin post patent expiry in India
Empagliflozin’s price drop reveals crucial market dynamics.
The rise of anti-obesity drugs like GLP-1 therapies in shaping India’s emerging markets
GLP-1 therapies are transforming India’s obesity treatment landscape.
India crossing 30 billion dollars in pharma exports for FY25 and what it means for global competitiveness
India’s pharma exports soar, boosting global market presence.
Reduced regulatory violations in Indian pharma as USFDA observation rates decline
Indian pharma sees fewer USFDA violations, boosting confidence.
Market behaviour in April 2025 and how price hikes and chronic therapies drove IPM growth
April 2025 saw dramatic price hikes fueling IPM growth.
How the streamlining of medical device clearance rules is changing regulatory timelines in Indian pharma
New rules are speeding up medical device approvals in India.
Challenges and volatility in pharma stocks in H1 2025 and the impact on investor sentiment
Pharma stocks faced turmoil, shaking investor confidence.